CA-VERIMATRIX
21.9.2021 17:47:12 CEST | Business Wire | Press release
Regulatory News:
Verimatrix , (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Ontario, Canada-based SSIMWAVE Inc. is one of its latest customers to integrate Verimatrix Code Protection technology.
IP theft is a growing threat to organizations worldwide. The Commission on the Theft of American Intellectual Property estimates that costs from IP losses are as high as $600 billion annually.
“Verimatrix has a lengthy and successful history in the media and entertainment space, so it made sense to turn to their code protection technologies,” said Peter Olijnyk , Vice President of Engineering at SSIMWAVE. “When you’re protecting the core foundation of your platform, Verimatrix’s transparent and timely process for getting up and running – not to mention in about a day or so – was reassuring and provides peace of mind for SSIMWAVE and our customers.”
A video quality innovator, SSIMWAVE evaluated numerous vendors and decided to integrate Verimatrix to safeguard its platform that ensures smooth video operations, distribution and optimization for streaming service providers, studios, content owners and content distributors.
“As an Emmy® award-winning technology provider recognized for significantly impacting television technology and engineering, SSIMWAVE knows it’s critical to choose the best possible security partner to protect our patented technologies against decompiling and inspection techniques frequently used by cybercriminals,” Olijnyk continued. “Video creators and streaming providers need to manage any degradations in video quality due to compression and other factors – and SSIMWAVE’s SSIMPLUS algorithm uniquely helps measure and understand that degradation and find the balance between cost savings and delivering the quality that viewers expect. In today’s world of everywhere entertainment, that’s highly valuable technology that demands proven protection. Verimatrix’s Code Protection technology, ease of integration and customer service were excellent.”
SSIMWAVE stands as the first technology provider capable of virtualizing and measuring how humans perceive video and applying its intelligence to real-world experiences. It provides fast, accurate and consistent measurements at every point from source to screen – through every delivery system, on every device, using a consistent 0-100 linear scoring metric. It’s this measurement that allows for the optimization that is so highly coveted.
“With core technologies that have helped power many of the biggest names in entertainment for decades, Verimatrix is pleased to now announce integrations of our Code Protection technology into platforms that service other areas of the video user experience,” said Asaf Ashkenazi , Chief Operating Officer and President at Verimatrix. “We see working with leaders such as SSIMWAVE as a natural progression for our business – helping protect the IP of fellow innovators within the vast media and entertainment space. Verimatrix understands the necessity of properly marrying user experience and IP integrity.”
About SSIMWAVE
SSIMWAVE
was founded in 2013 creating the Video Experience Automation category to enable assessment of video quality at scale so that video streaming services could reduce their distribution expenses and stop worrying about quality drop-offs and the high operational cost of traditional video assurance processes. The SSIMPLUS® quality metric powers our VQ Dial and Video Intelligence Suite products in order for customers to enjoy the peace of mind that comes from the only end-to-end solution that is correlated to human vision. We are located in Waterloo, Canada where we serve some of the largest media and entertainment customers around the world. Visit www.ssimwave.com
.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005061/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom